Satellos Bioscience (MSLE) Assets Average (2024 - 2026)
Satellos Bioscience's (MSLE) quarterly Assets Average came in at $53.6 million in Q1 2026, up 26.3% on a QoQ basis from $42.4 million in Q4 2024.
Satellos Bioscience (MSLE) Assets Average (2024 - 2026) Analysis & Trends
Satellos Bioscience (MSLE) has 2 years of Assets Average data on file, last reported at $53.6 million in Q1 2026.
- On a quarterly basis, Assets Average changed N/A year-over-year to $53.6 million in Q1 2026; TTM through Mar 2026 was $53.6 million, a N/A change from a year earlier, with the FY2025 full-year figure at $41.3 million, down 1.9% from the prior year.
- Assets Average for Q1 2026 stood at $53.6 million, up from $42.4 million in the prior quarter.
- Over the last five years, Assets Average for MSLE reached as high as $53.6 million in Q1 2026 and fell as low as $42.4 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 303.40 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 65.01 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 40.89 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 8.37 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 26.06 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 40.71 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | 795.91 Mn |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 2.30 Bn |
| 10 | Satellos Bioscience | 175.69 Mn | 175.69 Mn | - | 53.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 53.56 Mn |
| Dec 31, 2024 | 42.40 Mn |